Epigenetic Silencing of the Circadian Clock Gene CRY1 is Associated with an Indolent Clinical Course in Chronic Lymphocytic Leukemia

Disruption of circadian rhythm is believed to play a critical role in cancer development. Cryptochrome 1 (CRY1) is a core component of the mammalian circadian clock and we have previously shown its deregulated expression in a subgroup of patients with chronic lymphocytic leukemia (CLL). Using real-time RT-PCR in a cohort of 76 CLL patients and 35 normal blood donors we now demonstrate that differential CRY1 mRNA expression in high-risk (HR) CD38+/immunoglobulin variable heavy chain gene (IgVH) unmutated patients as compared to low-risk (LR) CD38−/IgVH mutated patients can be attributed to down-modulation of CRY1 in LR CLL cases. Analysis of the DNA methylation profile of the CRY1 promoter in a subgroup of 57 patients revealed that CRY1 expression in LR CLL cells is silenced by aberrant promoter CpG island hypermethylation. The methylation pattern of the CRY1 promoter proved to have high prognostic impact in CLL where aberrant promoter methylation predicted a favourable outcome. CRY1 mRNA transcript levels did not change over time in the majority of patients where sequential samples were available for analysis. We also compared the CRY1 expression in CLL with other lymphoid malignancies and observed epigenetic silencing of CRY1 in a patient with B cell acute lymphoblastic leukemia (B-ALL).

[1]  Eduard Batlle,et al.  The circadian molecular clock creates epidermal stem cell heterogeneity , 2011, Nature.

[2]  Aziz Sancar,et al.  Biochemical Analysis of the Canonical Model for the Mammalian Circadian Clock* , 2011, The Journal of Biological Chemistry.

[3]  C. Plass,et al.  Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. , 2011, Blood.

[4]  D. Oscier,et al.  Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia , 2011, Epigenetics.

[5]  R. Siebert,et al.  Gene dosage effects in chronic lymphocytic leukemia. , 2010, Cancer genetics and cytogenetics.

[6]  L. Donehower,et al.  Disrupting Circadian Homeostasis of Sympathetic Signaling Promotes Tumor Development in Mice , 2010, PloS one.

[7]  S. Gery,et al.  Circadian rhythms and cancer , 2010, Cell cycle.

[8]  Theodore R Holford,et al.  Molecular and Cellular Pathobiology Transcriptional Profiling Analyses , 2022 .

[9]  J. Stanford,et al.  Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. , 2009, Cancer research.

[10]  Paolo Sassone-Corsi,et al.  Metabolism and cancer: the circadian clock connection , 2009, Nature Reviews Cancer.

[11]  W. Hrushesky,et al.  Circadian Time-Dependent Tumor Suppressor Function of Period Genes , 2009, Integrative cancer therapies.

[12]  L. Klein-Hitpass,et al.  Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia , 2009, European journal of haematology.

[13]  Patricia A. Wood,et al.  THE CIRCADIAN CLOCK GENE PER1 SUPPRESSES CANCER CELL PROLIFERATION AND TUMOR GROWTH AT SPECIFIC TIMES OF DAY , 2009, Chronobiology international.

[14]  John M. Greally,et al.  A pipeline for the quantitative analysis of CG dinucleotide methylation using mass spectrometry , 2009, Bioinform..

[15]  T. Holford,et al.  Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. , 2009, Cancer research.

[16]  Shou‐Tung Chen,et al.  Disturbance of circadian gene expression in breast cancer , 2009, Virchows Archiv.

[17]  J. Lee,et al.  Loss of cryptochrome reduces cancer risk in p53 mutant mice , 2009, Proceedings of the National Academy of Sciences.

[18]  J. Garcia-conde,et al.  Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia , 2009, Haematologica.

[19]  I. Benet,et al.  Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups , 2009, Leukemia & lymphoma.

[20]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[21]  A. Pettitt,et al.  The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia , 2007, Leukemia.

[22]  Paolo Sassone-Corsi,et al.  Circadian Clock and Breast Cancer: A Molecular Link , 2007, Cell cycle.

[23]  Michele Pagano,et al.  SCFFbxl3 Controls the Oscillation of the Circadian Clock by Directing the Degradation of Cryptochrome Proteins , 2007, Science.

[24]  A. Sancar,et al.  Structure and function of animal cryptochromes. , 2007, Cold Spring Harbor symposia on quantitative biology.

[25]  Jan-Gowth Chang,et al.  Promoter methylation in circadian genes of endometrial cancers detected by methylation‐specific PCR , 2006, Molecular carcinogenesis.

[26]  L. Klein-Hitpass,et al.  Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status , 2006, Leukemia.

[27]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[28]  Cheng Chi Lee.  Tumor Suppression by the Mammalian Period Genes , 2006, Cancer Causes & Control.

[29]  Aziz Sancar,et al.  Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. , 2005, Cancer research.

[30]  L. Klein-Hitpass,et al.  Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia , 2005, Leukemia.

[31]  Emmanuel Barillot,et al.  Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..

[32]  R. Abseher,et al.  Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Sancar.  Regulation of the Mammalian Circadian Clock by Cryptochrome* , 2004, Journal of Biological Chemistry.

[34]  Cheng Li,et al.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..

[35]  D. Boivin,et al.  Circadian clock genes oscillate in human peripheral blood mononuclear cells. , 2003, Blood.

[36]  Peng Huang,et al.  The Circadian Gene Period2 Plays an Important Role in Tumor Suppression and DNA Damage Response In Vivo , 2002, Cell.

[37]  J. Dürig,et al.  CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia , 2002, Leukemia.

[38]  R. Stevens,et al.  Night shift work, light at night, and risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[39]  R. V. Van Gelder,et al.  Functional redundancy of cryptochromes and classical photoreceptors for nonvisual ocular photoreception in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Michael R. Green,et al.  Gene Expression , 1993, Progress in Gene Expression.